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NeuroepigeneticsModulation of gene expression is a constant and necessary event for mammalian brain function. An impor-
tant way of regulating gene expression is through the remodeling of chromatin, the complex of DNA, and
histone proteins around which DNA wraps. The “histone code hypothesis” places histone post-
translationalmodiﬁcations as a signiﬁcant part of chromatin remodeling to regulate transcriptional activity.
Acetylation of histones by histone acetyl transferases and deacetylation by histone deacetylases (HDACs) at
lysine residues are themost studied histone post-translationalmodiﬁcations in cognition and neuropsychi-
atric diseases. Here, we review the literature regarding the role of HDACs in brain function. Among the roles
of HDACs in the brain, studies show that they participate in glial lineage development, learning and mem-
ory, neuropsychiatric diseases, and even rare neurologic diseases. Most HDACs can be targeted with small
molecules. However, additional brain-penetrant speciﬁc inhibitors with high central nervous system expo-
sure are needed to determine the cause-and-effect relationship between individual HDACs and brain-
associated diseases.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The mammalian brain exercises numerous functions including
the maintenance of homeostasis within the body, sensorimotor abil-
ity, learning, memory, and behavior. All these functions require pre-
cise regulation of gene expression. For instance, the brain is able to
storememories for as little as a fewminutes to asmany as several de-
cades. Such ﬂexibility suggests that multiple mechanisms are in-
volved in altering neuronal function to generate short- to long-term
changes in the brain Dulac, 2010. One of the most important ways
of regulating gene expression is through the remodeling of chroma-
tin, the complex of DNA, and histone proteins around which DNA
wraps. Gene expression changes when the wrapping density of
DNA around the histones changes. Two main mechanisms account
for this chromatin remodeling: histone post-translational modiﬁca-
tions or DNA methylation. Most studies in the literature dealing
with these epigenetic changes are found in the cancer, developmen-
tal, and stem cell biology ﬁelds. A search for “chromatin remodeling”
on PubMed in June of 2014 reveals that out of more than 5400 peer-
reviewed papers, only about 300 are linked to brain-related studies.ation, Department of Psychi-
hool of Medicine, 1501 NW
1 305 243 8822.
mar),
. This is an open access article unOut of these, approximately half deal with histones. The range of pos-
sible histonemodiﬁcations includes the following: acetylation,meth-
ylation, ubiquitylation, phosphorylation, sumoylation, ribosylation,
and citrullination. Within these, the most studied modiﬁcation is
the acetylation of histones by histone acetyl transferases (HATs)
and the removal of acetyl groups from histones by histone
deacetylases (HDACs), the latter being the main focus of this review.
The post-translational modiﬁcations mentioned above occur all
along the histone sequence but are more prevalent at the N-termini
commonly referred to as histone tails. Other important components
in histone modiﬁcations include bromodomain-containing proteins
(termed reader proteins),which recognize speciﬁc acetylated histone
residues, in the presence of chemical moieties and chromatin-
modifying effectors, in order to affect gene expression (Campos and
Reinberg, 2009). It follows that HDAC activity is an important process
in regulating gene expression by physically affecting chromatin den-
sity and by regulating access to acetylated histone residues by reader
proteins. The observation that a combination of several histonemod-
iﬁcations are needed to regulate transcriptional activity has led to the
formulation of the “histone code hypothesis” (Campos and Reinberg,
2009; Strahl and Allis, 2000; Turner, 2000).More speciﬁcally, this hy-
pothesis stems from observations such as both low levels of histone
acetylation and high levels of trimethylated H4K20 and H3K27 typi-
cally resulting in silenced chromatin. Additionally, hyperacetylation,
and trimethylation at residues H3K4 and H3K36 have been
demonstrated to be marks of active transcription (Dulac, 2010). Fur-
thermore, acetylation at H3K9 and H3K14 has been linked toder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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deacetylation via HDACs are critical parts of the histone code
hypothesis.
Two categories of HDACs have been identiﬁed thus far: the “zinc-
dependent” ones and the “nicotinamide-adenine-dinucleotide
(NAD)–dependent” sirtuins. Depending on sequence similarity, the
zinc-dependent HDAC family members are composed of class I
(HDACs 1, 2, 3, and 8), classes IIa and IIb (HDACs 4, 5, 6, 7, 9, and
10), or class IV (HDAC 11). All of the zinc-dependent HDACs are
expressed in the brain. It is important to note that class I HDACs are
found mostly within the nucleus, whereas class II members shuttle
between the nucleus and cytoplasm (Gibson and Murphy, 2010).
An exception is found with HDAC6, which is located only in the cyto-
plasm. Isoforms of HDACs class I, II, and IV are expressed primarily in
neurons, in the brain (Broide et al., 2007). Although the expression of
all HDACs is relatively low in astrocytes, HDACs 2, 3, 4, 5, and 11 are
expressed in oligodendrocytes (Gräff and Tsai, 2013). Of the afore-
mentioned classes of HDACs, classes I and IIa are the most highly
expressed in brain regions that are associated with learning and
memory. The reader is directed to the review by Gräff and Tsai
(2013) for more in-depth coverage of this information (Gräff and
Tsai, 2013). The class III NAD-dependent sirtuins form a class of
deacetylases highly conserved from prokaryotes to eukaryotes, with
7 isoforms in humans, forming the SIRT gene family (Grozinger
et al., 2001). SIRTs 1 to 7 each have distinct cellular localization.
SIRTs 1, 2, 6, and 7 are found in the nucleus, whereas SIRTs 3, 4, and
5 are located in the mitochondria (Han, 2009; Michishita et al.,
2005). Histone deacetylase activity has only been conﬁrmed with
SIRTs 1, 2, 3, and 5 (Haigis and Sinclair, 2010; Han, 2009). All the
SIRTs, with the exception of SIRTs 2 and 5, present higher gene ex-
pression in fetal brain compared to adult brain (Michishita et al.,
2005). These data support the hypothesis that SIRTs may play crucial
roles in early brain development.
HDACs and brain development
It has been reported that maternal care of offspring has positive
effects on brain development and on the ability of offspring to cope
with stress in adult life. This has been experimentally linked to his-
tone acetylation and DNA methylation in rats. Indeed, pups of high-
grooming females show increased expression of the glucocorticoid
receptor compared to offspring of low-grooming females (Weaver
et al., 2004). The increased expression correlates with low levels of
DNA methylation and high levels of histone acetylation at exon 17
promoter of the glucocorticoid receptor gene, resulting in high bind-
ing of the transcription factor EGR1, known to regulate this gene
(Weaver et al., 2004). Conversely, offspring of low-groomingmothers
present high levels of DNA methylation and low levels of histone
acetylation at this region, resulting in low EGR1 binding. Interesting-
ly, injection of the HDAC inhibitor trichostatin A (TSA) in the brain of
adult offspring from low-grooming mothers ablates the negative ef-
fects on glucocorticoid receptor expression (Weaver et al., 2004).
These data suggest that acetylation is a crucial step in the establish-
ment of brain glucocorticoid receptors early in life and HDACs are
probably activated in offspring by maternal behavior. These data do
not, however, preclude a possible role of HATs in this type of epige-
netic programming. Further support for the role of acetylation in
brain development comes from studies showing that the class III
HDAC SIRT1 is critical for driving the differentiation of cells toward
an astroglial lineage, away from a neuronal fate Prozorovski et al.,
2008. However, nonacetylation roles of HDACs may also be critical
in brain development because the class III HDAC SIRT4 that shows
no deacetylase activity also appears to play a signiﬁcant role in the
development of astroglia from radial glia, in association withglutamate dehydrogenase-1 (Komlos et al., 2013). Indeed, SIRT4 is
highly expressed in astrocytes in the postnatal brain and in radial
glia in embryonic tissues, whereas expression decreases during
development.
HDACs and memory
Learning and memory are subject to rigorous epigenetic control
involvingmultiplemechanisms of neuronal chromatinmodiﬁcations.
Since the report by Swank and Sweatt (2001) showed that exposing
mice to novel tastes increased histone lysine acetylation due in part
to increased HAT activity in the insular cortex, there have been nu-
merous reports suggesting that histone acetylation is involved in
memory formation. For instance, it is well established that the
cAMP response element binding protein (CREB) binding protein
(CBP) is important for memory formation and that CBP works as a
transcription factor and as an HAT. Korzus et al. (2004) have shown
that only long-term memory is impaired in a transgenic mouse
model where the HAT activity of CBP is removed. The authors do
not observe any negative effect on short-termmemory in the absence
of HAT. This long-term memory impairment, however, is rescued
when the animals are treated with the pan HDAC inhibitor TSA
(Korzus et al., 2004), demonstrating that acetylation is critical for
the stabilization of short-term memory into long-term memory. In
a seminal paper where both HDAC1 and HDAC2 were overexpressed
and deleted in 4 novelmouse lines, HDAC2, but not HDAC1,was iden-
tiﬁed as a regulator of associative and spatial memory (Guan et al.,
2009). HDAC2-overexpressing mice showed impaired memory per-
formance, whereas HDAC2-knockout mice had enhanced memory
performance.
Reviews of the literature from 2001 to 2014 indicate that most
studies linking acetylation to memory have utilized HDAC inhibitors
to demonstrate that increased lysine acetylation resulting from the in-
hibition of HDACs enhances cognition in rodents (Korzus et al., 2004;
Levenson and Sweatt, 2005; Swank and Sweatt, 2001). Different
HDACs appear to have speciﬁc roles in different types of learning and
memory regulation. By pharmacologically inhibiting the class I HDAC,
HDAC1 with the small molecule MS-275, Bahari-Javan et al. (2012)
demonstrated that fearmemory extinction is impaired. This conclusion
is further supported by the observation that overexpressing HDAC1 in
the mouse hippocampus results in enhanced extinction of contextual
fear memories (Bahari-Javan et al., 2012). Bahari-Javan et al. (2012)
also show that memory extinction training resulted in deacetylation
of the HDAC1 target, H3K9 (Bahari-Javan et al., 2012). Further support
for the role of class I HDACs in fear memory extinction comes from the
recent ﬁndings of Hait et al. (2014) who have reported that the phos-
phorylated form of FTY720 (ﬁngolimod), an Food and Drug Adminis-
tration–approved drug for treatment of multiple sclerosis, inhibits
class I HDAC activity and facilitates fear extinction memory (Hait
et al., 2014). Inhibition of HDAC3, the most highly expressed class I
HDAC in the brain, has been shown to increase acetylation of H4K8
and enhance long-term object recognition memory in mice, implying
that HDAC3 is a negative regulator of long-term memory formation
(McQuown et al., 2011; Malvaez et al., 2013).
The class IIa HDAC, HDAC4, has been shown to play an important
role in synaptic plasticity and memory formation (Kim et al., 2012;
Sando et al., 2012). Studies conducted by Kim et al. (2012) as well as
those by Sando et al. (2012) show that silencing or truncation of
HDAC4 results in impairment of spatial learning and memory, as
assessed by the Morris water maze or the Barnes Maze. Interestingly,
Kim et al. (2012) do not observe any memory impairment in the ab-
sence of HDAC5, suggesting that within class IIa HDACs, the effect on
learning and memory is speciﬁc to HDAC4. Interestingly, Agis-Balboa
et al. (2013) have shown thatHDAC5 is important for the consolidation
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studies suggest that HDAC5 is not involved in spatial memory but cru-
cial for fear memory formation. Other studies need to be performed to
determine whether the other class IIa HDACs (HDACs 7 and 9) affect
learning and memory. In the category of class III HDACs, SIRT1 is the
most studied, and it has been shown by genetic manipulation (i.e.,
truncation or silencing) and pharmacologic studies to be crucial for es-
tablishment of fear and spatial learning as well as synaptic plasticity
(Gao et al., 2010).Moreover, SIRT1 has been shown to limit the expres-
sion ofmicro-RNAmi-134, the latterwhich is known to down-regulate
the translation of the memory-associated genes CREB and brain-de-
rived neurotrophic factor (BDNF) (Gao et al., 2010).
Fass et al. (2013), through screening of a small molecule library
structurally related to known HDAC inhibitors, have identiﬁed a
novel HDAC inhibitor that up-regulates the activation of CREB-
mediated transcription. They have named this compound crebinostat
and have further shown that it increases bdnf and granulin expres-
sion, up-regulates synapsin1 puntae dendritic density in cultured
mouse primary neurons, and enhances fear learning and memory in
wild-type mice (Fass et al., 2013). The authors have shown that
crebinostat has no signiﬁcant inhibition of class IIa HDACs nor class
IIb (HDAC8) but present signiﬁcant and potent inhibition of the activ-
ity of class I HDACs 1, 2, and 3 and class IIb (HDAC6). These data pres-
ent yet another HDAC inhibitor that may be useful as a lead to
develop cognitive enhancers against neurodegenerative diseases.
Environmental enrichment can be considered a classic epigenetic
example of how one's living milieu can have profound effects on
one's genes. Several reports support that environmental enrichment
can enhance cognition in aged animals or in neurodegenerative dis-
ease mouse models (Fischer et al., 2007; Frick et al., 2003; Huang
et al., 2006; Pereira et al., 2007). Such an effect on synaptic plasticity
is inherently linked to effects on gene expression. Fischer et al. (2007)
have shown that environmental enrichment causes global increase in
histone acetylation at residues H3K9, H3K14, H4K5, H4K8, and
H4K12 in the hippocampus of the Alzheimer disease (AD) mouse
model, CK-p25 mice. This acetylation proﬁle correlated with in-
creased long-termmemory. They further demonstrate that treatment
of these mice with the nonspeciﬁc HDAC inhibitor sodium butyrate
results in a hippocampal histone acetylation proﬁle that resembles
one of the mice that were exposed to environmental enrichment.
Furthermore, sodium butyrate increased the expression of synaptic
proteins in the brain of treated animals compared to controls
(Fischer et al., 2007).
HDACs in neuropsychiatric diseases
Alzheimer disease
Broide et al. (2007) have reported that HDAC2, but not HDAC1 or
HDAC3, is up-regulated in 2 mouse models of AD, the CK-p25 and
5XFAD mouse models (Broide et al., 2007). Using the Tg2576 AD
mouse model (Hsiao et al., 1996) harboring the amyloid precursor
protein (APP) Swedish mutation (Mullan et al., 1992), Ricobaraza
et al. (2012) shows that the HDAC inhibitor 4-phenylbutyrate can
reinstate fear learning; reduce intraneuronal beta amyloid (Aβ);
increase dendritic spine density; and increase expression of the N-
Methyl-D-aspartate receptor subunit NR2B, a plasticity-related
gene, regardless of the disease stage (Ricobaraza et al., 2012). Com-
prehensive work by Sung et al. (2013) has further implicated
HDACs classes I and II in AD pathogenesis by demonstrating that a
mercaptoacetamide-based class II HDAC inhibitor (W2) and a
hydroxamide-based class I and II inhibitor (I2) can reduce Aβ (Sung
et al., 2013). More speciﬁcally, these authors show in vitro that com-
pound I2 decreases expression of the APP cleaving enzymesβ- andγ-secretase, concomitantwith the observed decrease in Aβ1-40. Surpris-
ingly, the decrease in γ-secretase does not result in Aβ1-42 decrease.
These authors also show in vitro that the more speciﬁc brain-pene-
trant compound W2 reduces only γ-secretase protein expression
and attenuates both Aβ1-40 and Aβ1-42 (Sung et al., 2013). They fur-
ther show in vivo that compoundW2 reduces both common ADphe-
notypes Aβ and tau phosphorylation in the brain of aged triple
transgenic AD mouse model hAPP 3xTg AD (Oddo et al., 2003), as
well as improves cognition Sung et al., 2013. Down-regulation of
tau expression in vivo has also been observed with the HDAC inhibi-
tor crebinostat, a class I (HDAC 1, 2, and 3) and class IIb (HDAC 6) in-
hibitor (Fass et al., 2013). Considering that compoundW2 is a class II
speciﬁc inhibitor, it is possible that the effects observed on tau ex-
pression be due to inhibition of HDAC6. Testing the hypothesis that
HDAC6 inhibition reduces tau expressionmay bewarranted. Further-
more, HDAC6 has been shown to recruit misfolded protein cargo to
dynein motors for transport to aggresomes, suggesting a possible
role in protein aggregation (Kawaguchi et al., 2003), a major pheno-
type in neurodegenerative diseases such as Alzheimer, Parkinson,
and Huntington diseases. These data support targeting the inhibition
of class II HDACs is a sound strategy to counter AD pathogenesis.
However, the inhibition of some class II HDACsmay be harmful in
AD. Agis-Balboa et al. (2013) have recently shown in 10-month-old
AβPP/PS1-21 ADmice that removal of HDAC5 is detrimental to learn-
ing and memory and increased decline in context and tone-
dependent fear memory. On the other hand, the HDAC SIRT1, a
class III HDAC, has been reported to be a potential target in AD be-
cause it appears to promote the nonamyloidogenic processing of
the APP by up-regulating the activity of the α-secretase enzyme
gene ADAM10 (Donmez et al., 2010). Furthermore, a combination
of caloric restriction and oral administration of the selective SIRT1 in-
hibitor SRT3657 has been shown to delay the onset of neurodegener-
ation in the CK-p25 mice. These data suggest that HDAC speciﬁcity is
crucial in devising strategies to mitigate HDAC-mediated AD-related
pathology.
Stress, depression, and schizophrenia
Covington et al. (2009) have reported on the beneﬁts of HDAC in-
hibition against depression. These authors show that treatment of the
nucleus accumbens with HDAC inhibitors (suberoylanilide
hydroxamic acid [SAHA] andMS-275) results in increased acetylation
of histone H3K14 and signiﬁcant antidepressant like effects in the
chronic social defeat stress model in mice (Covington et al., 2009).
Furthermore, they show thatMS-275 reverses global gene expression
patterns triggered by stress. For instance, genes such as CAMKII,
CREB, ERK, REST, and nAchR that are down-regulated by stress are
found to be up-regulated by MS-275 in the brain (Covington et al.,
2009). Uchida et al. (2011) have later linked HDAC2 to stress and de-
pression in mouse models. They report that chronic stress increases
HDAC2 level and its binding to the glial-derived neurotrophic factor
(Gdnf) promoter, reducing expression of Gdnf in the nucleus accum-
bens. They further demonstrate that genetically reducing the avail-
ability of HDAC2 in mice resulted in attenuation of depression-like
behavior due to exposure to stress. Both messenger RNA and protein
expression of HDACs 1, 3, and 5 have been shown to be altered in
depression, bipolar disorder, and schizophrenia (Benes et al., 2007;
Covington et al., 2009; Hobara et al., 2010). Kurita et al. (2012) report
that the expression of HDAC2, but not HDAC1 or HDAC4, is elevated
in the frontal cortex of schizophrenic patients treated with atypical
antipsychotics (Rudenko and Tsai, 2014). Moreover, these authors
show that treatment with the antipsychotic clozapine caused an in-
crease in binding of HDAC2 to themGluR2 promoter. Clozapine treat-
ment associated with decrease in histone H3 acetylation at the
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expression in both human and mouse frontal cortex (Rudenko and
Tsai, 2014).
One of themost comprehensive reports on the effects of antidepres-
sants andmood stabilizers onHDAC gene expression is by Ookubo et al.
(2013). In different areas of the brain of C57Bl6mice, these authors have
observed region-speciﬁc effects of commonly prescribed drugs on his-
toneH3acetylation (AcH3) andHDACgeneexpression. There is a signif-
icant increase of histone H3 acetylation in the nucleus accumbens after
15 days of treatment with sodium valproate, lithium chloride,
lamotrigine, levetiracetam, olanzapine, clozapine, clomipramine, (S)-
citalopram oxalate, or duloxetine hydrochloride (Ookubo et al., 2013).
In the striatum, treatment with clomipramine, (S)-citalopram oxalate,
duloxetine hydrochloride, mirtazapine, carbamazepine, lamotrigine, le-
vetiracetam, olanzapine, or clozapine results in signiﬁcant increases of
both HDAC2 andHDAC3 expression (Ookubo et al., 2013). In the cingu-
late cortex, clomipramine, mirtazapine, sodium valproate, carbamaze-
pine, lamotrigine, levetiracetam, olanzapine, or clozapine signiﬁcantly
increases HDAC3 expression. In the amygdala, the drugs (S)-citalopram
oxalate, duloxetine hydrochloride, mirtazapine, sodium valproate, car-
bamazepine, lamotrigine, levetiracetam, and olanzapine all result in
signiﬁcant increases inHDAC5 expression. Interestingly, the antidepres-
sant imipramine has been shown to selectively down-regulate HDAC5
in the hippocampus of a mouse model of depression (Tsankova et al.,
2006). Moreover, overexpression of HDAC5 has been shown to block
the antidepressive effects of imipramine in that model (Tsankova
et al., 2006). Taken together, these data suggest that directly targeting
HDACs may be an alternate way to attenuate depression and mood
disorders.
Addiction
Chronic but not acute exposure to cocaine induces HDAC5 phos-
phorylation and nuclear export in the nucleus accumbens, thus in-
creasing transcription of HDAC5 target genes. As well, silencing
Hdac5 gene expression in the nucleus accumbens of animal models
of addiction causes hypersensitive behavior response to chronic but
not acute cocaine treatment (Renthal et al., 2007). Concordantly,
Host et al. (2011) suggest nuclear export of HDAC5 after that self-
administration of cocaine because they observe a decrease in nuclear
localization of both HDAC5 and phosphorylated HDAC5 (Host et al.,
2011). These data suggest that HDAC5 may be a good target against
cocaine addiction. Taking a broader approach, Kennedy et al. (2013)
have actually shown that inhibiting class I HDACs in the nucleus ac-
cumbens of mice blocks cocaine-induced plasticity, altering co-
caine-triggered behavioral adaptations (Kennedy et al., 2013).
Moreover,Malvaez et al. (2013) also show that pharmacologic inhibi-
tion of the class I HDAC3 with the selective inhibitor RJFP966 en-
hances extinction of a previously established cocaine-seeking
behavior, while promoting acetylation of H3K14 and up-regulating
learning-associated gene expression within the infralimbic cortex,
hippocampus, and nucleus accumbens. Other HDACs linked to co-
caine addiction are HDAC2 (concordant with the Kennedy et al.,
2013 study) and the class IV HDAC11, which signiﬁcantly increase
in rat brain after cocaine self-administration (Host et al., 2011).
Brain changes due to alcohol addiction have also been linked to
HDAC activity (You et al., 2014). In rats, treatment with TSA reverses
the decrease in BDNF expression observed in the amygdala during eth-
anol dependence and reduces anxiety-like behaviors during ethanol
withdrawal (You et al., 2014). In the case of morphine addiction,
Wang et al. (2014) have shown that pretreatment in the
intrabasolateral amygdala pretreatmentwith the class I and II HDAC in-
hibitor TSA resulted in enhanced morphine-induced conditioned place
preference acquisition and expression, facilitated extinction, andreduced reinstatement of morphine-induced conditioned place prefer-
ence Wang et al., 2014. There is ample evidence suggesting that
targeting HDACs is a good strategy to counter drug and alcohol
addiction.
Autism spectrum disorders
In utero exposure to the HDAC inhibitor valproic acid (VPA) has
been linked to autism spectrum disorder in humans and has been
shown to trigger social cognition deﬁcits in rodents (Cohen et al.,
2013; Moldrich et al., 2013). Similar abnormal social behaviors are
observed when mice are treated with the HDAC inhibitor TSA in
utero (Moldrich et al., 2013). This suggests that HDACs play an im-
portant role in brain development mechanisms that lead to autism.
Kim et al. (2014) have identiﬁed signiﬁcant increases of acetylation
at the promoter of the transcription factor Pax-6 and subsequent
Pax-6 gene up-regulation in the brain of rats that are exposed prena-
tally to VPA, TSA, or sodium butyrate. These authors go on to show
that with gene silencing experiments, Pax6 modulates cortical gluta-
matergic neuronal differentiation in thedevelopingbrain, resulting in
autism-like behavior in rats exposed to VPA in utero (Kim et al.,
2014). On the other hand, the negative effects that occur after in
utero exposure do not appear during postnatal chronic administra-
tion of HDAC inhibitors (Foley et al., 2012, 2014). In a rodent model
of autism spectrumdisorders, chronic administration of theHDAC in-
hibitors pentyl-4-yn-VPA (a VPA analog) and SAHA has been shown
to signiﬁcantly improve deﬁcits in social cognition using the social
approach avoidance paradigm (Foley et al., 2014). These effects
have been linked to increased acetylation of H3K8 by both pentyl-
4-yn-VPA and SAHA in the cerebellar cortex. Interestingly, only
pentyl-4-yn-VPA presents a decrease of acetylation H3K9 and in-
creased acetylation at H3K14 (Foley et al., 2014).
An analysis of rare copy number variations in more than 2000 pa-
tients has recently linked the class IIa HDAC9 to increased risk of au-
tism (Pinto et al., 2014). However, the function of this elevated
HDAC9 expression is not known. Experimentswhere HDAC9 is either
silenced or overexpressed need to be conducted to determinewheth-
er HDAC9 is protective or contributes to autism pathology.
HDACs in rare neurologic disease
Very little work has been done regarding the role of HDACs in
neurologic disorders; however, a few studies show great promise.
HDACs have been proposed as a target against the autosomal reces-
sive neurodegenerative disorder Friedreich ataxia (FRDA) (Herman
et al., 2006), a disease predominantly caused by a homozygous GAA
repeat expansionwithin the FXN gene that result in a frataxin protein
deﬁcit. This deﬁcit is due to epigenetic changes and heterochromatin-
mediated gene silencing (Al-Mahdawi et al., 2008; De Biase et al.,
2009). Sandi et al. (2011) have shown that treating FRDA transgenic
mice with pimelic o-aminobenzamide HDAC inhibitors 106, 109, and
136 results in amelioration of FRDA phenotypes (Sandi et al., 2011).
Compounds 109 and 106 improved motor coordination, whereas
compounds 109 and 136 increased locomotor activity.
Treatmentwith theHDAC inhibitor SAHAof amousemodel of the
rare genetic disorder Rubinstein-Taybi syndrome (a disease charac-
terized by mutations in the gene that encodes the CBP and severe
cognitive deﬁcits) results in reversal of memory deﬁcit in fear condi-
tioning (Alarcón et al., 2004). These data show that although CBP-
mediated HAT activity is negatively affected by CBP mutations, it is
possible to increase acetylation and ameliorate cognition bymodulat-
ing HDAC activity in Rubinstein-Taybi syndrome.
Another rare neurologic disorder, Alexander disease, a leukodys-
trophy that involves the destruction of myelin, has been linked to
Table 1
HDACs and associated brain functions.
HDAC Class Brain function References
HDAC1 I Molecular switch between neuronal survival and death,
negative regulator of fear extinction in mice, negative regulator of mood disorders
Bahari-Javan et al. (2012), Bardai et al. (2012),
Schroeder et al. (2013), Morrison et al. (2006)
HDAC2 I Negative regulator of memory formation, negative regulator of mood disorder,
up-regulated in Alzheimer's disease models
Broide et al. (2007), Guan et al. (2009), Schroeder et al. (2013),
Morris et al. (2013)
HDAC3 I Neuronal cell death through interaction with HDAC1, neurotoxicity mediated
by mutant huntingtin (htt) in Huntington disease
Bardai et al. (2012, 2013)
HDAC4 IIa Risk for autism spectrum disorders, neuronal cell survival, synaptic plasticity
and memory, depression
Sando et al. (2012), Pinto et al. (2014), Majdzadeh et al. (2008),
Sarkar et al. (2014)
HDAC5 IIa Blocking effect of antidepressant agent imipramine, negative regulator of
BDNF expression, up-regulated in cocaine addiction
Tsankova et al. (2006), Renthal et al. (2007), Host et al. (2011)
HDAC6 IIb Up-regulated in Rett syndrome model, negative effect on BDNF trafﬁcking,
T-cell regulation in neuroinﬂammation after brain ischemia,
tau gene expression in Alzheimer's disease, neuronal migration defect in epilepsy
Fass et al. (2013), Xu et al. (2014), Liesz et al. (2013),
Salmi et al. (2013)
HDAC7 IIa Neuroprotection against apoptosis Ma and D’Mello (2011)
HDAC8 I Negative regulator of declarative and nondeclarative memory Yang et al. (2013)
HDAC9 IIa Risk for autism spectrum disorders, reduced expression in schizophrenia,
expressed exclusively in postmitotic and mature neurons
Pinto et al. (2014), Lang et al. (2011)
HDAC10 IIb Not much is known about brain function, decreased expression in medial
hypothalamus during fasting behavior, promoter of autophagy in neuroblastoma
Funato et al. (2011), Oehme et al. (2013a)
HDAC11 IV Up-regulated after cocaine self-administration, decreased expression
in medial hypothalamus during fasting behavior, regulates expression
of brain speciﬁc N-acetylglucosaminyltransferase-IX
Host et al. (2011), Funato et al. (2011), Kizuka et al. (2014)
SIRT1 III Promote nonamyloidogenic processing of APP, up-regulate BDNF and
CREB expression, down-regulate mi-134, enhance memory,
neuroprotective against wallerian degeneration
Gao et al. (2010), Donmez et al. (2010), Araki et al. (2004),
Qin et al. (2006)
SIRT2 III Suppressor of microglial activation and brain inﬂammation,
negative regulator of neuronal cholesterol
Pais et al. (2013), Taylor et al. (2011)
SIRT3 III Increased by reactive oxygen species in Alzheimer's disease,
neuroprotective
Weir et al. (2012)
SIRT4 III Regulation of glia development Komlos et al. (2013)
SIRT5 III Increased expression in brain and spinal cord of amyotrophic
lateral sclerosis patients
Körner et al. (2013)
SIRT6 III Prevention of obesity; decreased in cerebral ischemia,
possible role in HMGB1-mediated inﬂammation after cerebral ischemia
Lee et al. (2013), Schwer et al. (2010)
SIRT7 III None reported
24 C.-H. Volmar, C. Wahlestedt / Neuroepigenetics 1 (2015) 20–27mutations in the predominant alpha isoform of glial ﬁbrillary acidic
protein (Brenner et al., 2001; Messing et al., 2010). Recently,
Melchionda et al. (2013) have reported in 2 siblings with adult-Table 2
Small molecules that target HDACs with reported brain effects.
HDAC Class Drugs with reported brain effects Refe
HDAC1 I Crebinostat, entinostat (MS-275), SAHA, compound 60,
valproic
acid, phosphorylated-FTY720 (ﬁngolimod), HDACi 4b, HDACi
228
Bah
(20
Fass
HDAC2 I Crebinostat, SAHA, trichostatin A, apicidin, compound 60,
entinostat (MS-275), valproic acid, phosphorylated-FTY720
(ﬁngolimod)
Hait
Fole
HDAC3 I Crebinostat, HDACi 4b, 136, RJFP966, apicidin, SAHA, entinostat
(MS-275), valproic acid, phosphorylated-FTY720 (ﬁngolimod)
Hait
Fass
HDAC4 IIa SAHA, trichostatin A, sodium butyrate Sark
HDAC5 IIa 4-Phenylbutyrate, SAHA Yeh
HDAC6 IIb Crebinostat, tubastatin A, tubacin, bufexamac, SAHA, ACY-738
and ACY-775
Sch
Kop
HDAC7 IIa SAHA Hait
HDAC8 I NBM-T-L-BMX-OS01, valproic acid, phosphorylated-FTY720
(ﬁngolimod)
Hait
HDAC9 IIa SAHA Yeh
HDAC10 IIb Tubastatin A, bufexamac Oeh
HDAC11 IV Trichostatin A Kizu
SIRT1 III Resveratrol, SRT1720, SRT3657 Zha
SIRT2 III 3-(1-azepanylsulfonyl)-N-(3-bromphenyl) benzamide
(aka AK 7)
Tay
SIRT3 III None reported
SIRT4 III None reported
SIRT5 III Suramin Sch
SIRT6 III Nicotinamide Bea
SIRT7 III None reportedonset Alexander disease, characterized by cognitive impairment and
motor neuron disease, that a non-neutral HDAC6 variant modulated
the phenotype of a mutant alternative glial ﬁbrillary acidic proteinrences
ari-Javan et al. (2012), Hait et al. (2014), Schroeder et al. (2013), Foley et al.
12),
et al. (2013), Shein and Shohami (2011), Thomas et al. (2008), Jia et al. (2012)
et al. (2014), Schroeder et al. (2013), Fass et al. (2013), Hobara et al. (2010),
y et al. (2012), Shein and Shohami (2011), Mielcarek et al. (2011)
et al. (2014), Malvaez et al. (2013), Schroeder et al. (2013), Foley et al. (2012),
et al. (2013), Shein and Shohami (2011), Thomas et al. (2008), Jia et al. (2012)
ar et al. (2014), Mielcarek et al. (2011), Matsuda et al. (2011), Yeh et al. (2013)
et al., 2013
roeder et al. (2013), Salmi et al. (2013), Fass et al. (2013), Jochems et al. (2014),
pel and Timmusk (2013), Oehme et al. (2013b)
et al. (2014)
et al. (2014), Yang et al. (2013), Shein and Shohami (2011)
et al. (2013)
me et al. (2013b)
ka et al. (2014)
o et al. (2013), Graff et al. (2013), Gueguen et al. (2014)
lor et al. (2011), Chopra et al. (2012)
uetz et al. (2007), Amin et al. (2008)
uharnois et al. (2013), Hoane et al. (2008)
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logic diseases have epigenetic components guiding the expression of
disease-related proteins. Considering that many of the rare diseases
are monogenic, it is thus plausible that such chromatin remodeling
strategies will be successful in silencing or activating the gene of in-
terest for such diseases.
Concluding remarks
As can be seen in Table 1, HDACs play important roles in cognition as
well as psychiatric and neurologic diseases. HDACs have awide range of
functions in the brain, and the inhibition of different isoforms has been
reported to be beneﬁcial against AD, Huntington disease, traumatic
brain injury, post-traumatic stress disorder, stress, depression, and ad-
diction. However, the few drugs that have reached clinical trials so far
have shown high side effects in patients. The working hypothesis is
that the drugs are not speciﬁc enough or that the dose regimen used
has been too high and not optimal.
Despite the obvious correlation of HDACswith long-term changes
in brain function, little is known of their exact mechanism of action
on neuronal activity. Frommost of the correlative studies that report
either increased or decreased expression of various HDACs, it is un-
clear whether the said HDACs operate upstream or downstream in
brain disease pathogenesis. Indeed, correlation does not necessarily
mean causation, and someHDACs have been shown to play beneﬁcial
roles against disease.Mechanistic studies are coming to lightwith the
advent of new technology allowing in-depth analysis after chromatin
immunoprecipitation, but they are difﬁcult to conduct pharmacolog-
ically due to the lack of speciﬁcity of current small molecules. It has
indeed been difﬁcult to design highly speciﬁc HDAC inhibitors be-
cause of the sequence similarity of the zinc-containing catalytic site
of the different HDACs. As can be seen in Table 2, most of the current-
ly available small molecule HDAC inhibitors affect the activity of sev-
eral HDACs within a class and oftentimes also affect different classes
of HDACs.
It is important to note that all HDAC effects on brain function are
likely not due to deacetylase activity. Numerous reports have pre-
sented in other systems that HDACs have modes of action on sub-
strates through different mechanisms. For instance, SIRT4 has been
reported to be an inhibitor of glutamate dehydrogenase and not to
have any deacetylase activity in pancreatic beta cells (Haigis et al.,
2006). Also, SIRT5 has been shown to bind to desuccinylate and acti-
vate super oxide dismutase-1 to eliminate reactive oxygen species, a
function independent of deacetylation (Lin et al., 2013). It is thus
plausible that many of the functions observed with HDACs in the
brain be due to secondary effects on yet unidentiﬁed substrates of
particular HDACs.
Of note is also the fact that HDACs have contributed to amodiﬁca-
tion of the term epigenetics in recent years. It no longer only applies
to changes in histonemarks or DNA tags that affect the expression of
genes/traits transgenerationally, without affecting the DNA se-
quence. As Dulac (2010) wrote in her review, the term epigenetics
is often used nowadays to explain when environmental conditions
or random developmental events affect “physiological traits, behav-
ioral traits and disease susceptibility from the early perinatal period
into adulthood.” Following these guidelines, one can safely state
that HDACs play a dynamic role in the brain and allow for epigenetic
adaptation to changes in the environment.
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